What’s Hot And What’s Not For Sofinnova

Around 75% of the €1.20bn ($1.26bn) Sofinnova Partners has raised in the past year will be going on biotech and chairman Antoine Papiernik has been musing on the therapeutic areas that are most likely to attract investment from Europe’s leading life science venture capital firm.

Oncology will always be interesting to investors given it is such a big market but Papiernik claimed that there were fewer investments in the space “not because cancer is being cured, far from it, but the bar has gone up and it’s more difficult to develop drugs in oncology